BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 8138958)

  • 1. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X; Farre M; Cami J
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1988 Aug; 246(2):441-8. PubMed ID: 2457074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1987 Mar; 240(3):900-10. PubMed ID: 3559982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Jan; 248(1):127-34. PubMed ID: 2913267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Aug; 250(2):485-91. PubMed ID: 2760839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the subjective, psychomotor and physiological effects of intravenous pentazocine and morphine in normal volunteers.
    Zacny JP; Hill JL; Black ML; Sadeghi P
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1197-207. PubMed ID: 9732379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval II.
    Kirby KC; Stitzer ML; Heishman SJ
    J Pharmacol Exp Ther; 1990 Nov; 255(2):730-7. PubMed ID: 2243350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug discrimination in human postaddicts: agonist-antagonist opioids.
    Preston KL; Bigelow GE; Bickel WK; Liebson IA
    J Pharmacol Exp Ther; 1989 Jul; 250(1):184-96. PubMed ID: 2473187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
    Jones HE; Bigelow GE; Preston KL
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased analgesic potency of mu agonists after continuous naloxone infusion in rats.
    Paronis CA; Holtzman SG
    J Pharmacol Exp Ther; 1991 Nov; 259(2):582-9. PubMed ID: 1658305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
    Schuh KJ; Walsh SL; Bigelow GE; Preston KL; Stitzer ML
    J Pharmacol Exp Ther; 1996 Aug; 278(2):836-46. PubMed ID: 8768738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute physical dependence: time course and relation to human plasma morphine concentrations.
    June HL; Stitzer ML; Cone E
    Clin Pharmacol Ther; 1995 Mar; 57(3):270-80. PubMed ID: 7697945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers.
    Preston KL; Bigelow GE
    J Pharmacol Exp Ther; 1993 Feb; 264(2):813-23. PubMed ID: 7679737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute physical dependence in man: effects of naloxone after brief morphine exposure.
    Bickel WK; Stitzer ML; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1988 Jan; 244(1):126-32. PubMed ID: 3335995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users.
    Zacny JP
    Drug Alcohol Depend; 2005 Nov; 80(2):273-8. PubMed ID: 16005162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.